Your session is about to expire
← Back to Search
Neuroprotective Agent
Neuroprotective Agents for Ischemic Stroke
Phase 1
Recruiting
Led By Thomas W Link, MD, MS
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Angiography must reveal a thromboembolism which is completely occluding flow within the intracranial portion of the internal carotid artery, the M1 or proximal M2 portions of the middle cerebral artery
Participants must meet criteria for intra-arterial thrombectomy as determined and documented by the Stroke Neurology and Interventional Neuroradiology attending physicians at Northshore University Hospital
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 24 hours of treatment
Awards & highlights
Study Summary
This trial is testing whether it is safe to give patients a cocktail of neuroprotective drugs immediately after they have a stroke, in order to try to improve long-term outcomes.
Who is the study for?
This trial is for adults aged 18-90 with acute ischemic stroke due to large vessel occlusion, who are eligible for intra-arterial thrombectomy. Excluded are pregnant or lactating women, those with certain heart conditions, renal insufficiency, severe liver issues, systemic lupus erythematosus, idiopathic intracranial hypertension, prior therapeutic anticoagulation or known allergies to contrast dye or trial drugs.Check my eligibility
What is being tested?
The study tests the safety and feasibility of delivering a mix of neuroprotective agents (cold saline, minocycline and magnesium sulfate) directly into the artery immediately after mechanical clot removal in stroke patients. It's an early-phase trial focusing on targeted therapy to damaged brain areas.See study design
What are the potential side effects?
Potential side effects may include reactions related to cold infusion such as shivering or discomfort at injection site; allergic responses; possible impact on kidney function from magnesium sulfate; and typical drug-related risks like nausea associated with minocycline.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My brain scan shows a complete blockage in a major brain artery.
Select...
I am eligible for a clot removal procedure as confirmed by specialists.
Select...
I have been diagnosed with a stroke caused by a blocked large blood vessel, confirmed by the Stroke Neurology team.
Select...
I am between 18 and 90 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 hours after procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours after procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Intracranial hemorrhage
Presence of serious adverse event
Secondary outcome measures
Functional outcome
Infarct volume
Side effects data
From 2017 Phase 2 trial • 22 Patients • NCT0174604320%
Peripheral Neuropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Armodafinil+Minocycline
Minocycline
Armodafinil
Trial Design
1Treatment groups
Experimental Treatment
Group I: Intra-arterial neuroprotective substancesExperimental Treatment1 Intervention
Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in "Study Description."
Find a Location
Who is running the clinical trial?
Northwell HealthLead Sponsor
458 Previous Clinical Trials
470,909 Total Patients Enrolled
1 Trials studying Ischemic Stroke
53 Patients Enrolled for Ischemic Stroke
Thomas W Link, MD, MSPrincipal InvestigatorNorthwell Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been on blood thinners before coming here.I have had a heart attack or been diagnosed with heart block.My blood flow restoration is rated TICI 0-2A.I have a major blood vessel blockage in my brain.I am not eligible for a specific type of blood vessel surgery.I am allergic to contrast dye, minocycline, or magnesium sulfate.My liver is not severely impaired.I have been diagnosed with increased brain pressure without a known cause.My kidney function is reduced with creatinine over 2.5 mg/dL.My brain scan shows a complete blockage in a major brain artery.I have been diagnosed with systemic lupus erythematosus.I am eligible for a clot removal procedure as confirmed by specialists.I have been diagnosed with a stroke caused by a blocked large blood vessel, confirmed by the Stroke Neurology team.I am between 18 and 90 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Intra-arterial neuroprotective substances
Awards:
This trial has 2 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger